Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Future directions for etoposide therapy.

F A Greco1

  • 1Department of Medicine, Vanderbilt University, Nashville, Tennessee.

Cancer
|January 1, 1991
PubMed
Summary
This summary is machine-generated.

A prolonged 21-day schedule of etoposide chemotherapy shows promise for treating germ cell tumors, lymphomas, and small cell lung cancer. This chronic oral administration may offer improved efficacy and absorption compared to standard schedules.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2015
Same author

Carcinoma of unknown primary with gastrointestinal profile: immunohistochemistry and survival data for this favorable subset.

International journal of clinical oncology·2013
Same author

Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2011
Same author

Cancer of unknown primary: progress in the search for improved and rapid diagnosis leading toward superior patient outcomes.

Annals of oncology : official journal of the European Society for Medical Oncology·2011
Same author

Molecular assignment of tissue of origin in cancer of unknown primary may not predict response to therapy or outcome: a systematic literature review.

Cancer treatment reviews·2008
Same author

Diagnostic and therapeutic management of cancer of an unknown primary.

European journal of cancer (Oxford, England : 1990)·2003
Same journal

Long-term outcomes of evolving treatment regimens in Ewing sarcoma survivors diagnosed 1970-1999: A report from the Childhood Cancer Survivor Study.

Cancer·2026
Same journal

Large-scale osteosarcoma sequencing reveals age-associated genomic architectures.

Cancer·2026
Same journal

EZH2 inhibitor tazemetostat voluntarily withdrawn from market.

Cancer·2026
Same journal

Nivolumab and chemotherapy combination approved for previously untreated Hodgkin lymphoma.

Cancer·2026
Same journal

Most older patients with advanced cancer prioritize QOL over extending survival: A secondary analysis of the GAP70+ trial found that among adults aged 70 and older with advanced, noncurable cancer, nearly three-quarters prioritized maintaining QOL.

Cancer·2026
Same journal

Real-world safety, prognostic, and design considerations in ketogenic diet trials for pancreatic cancer.

Cancer·2026
See all related articles

Area of Science:

  • Oncology
  • Pharmacology
  • Cancer Therapeutics

Background:

  • Etoposide is a key chemotherapeutic agent for germ cell tumors, lymphomas, and small cell lung cancer (SCLC).
  • Optimal etoposide dosing schedules are evolving, with schedule dependency being critical for efficacy.

Purpose of the Study:

  • To evaluate the efficacy and absorption of a prolonged 21-day oral etoposide administration schedule.
  • To explore the potential of chronic etoposide in resistant tumors and specific cancer types.

Main Methods:

  • Phase II studies involving chronic oral etoposide administration (50 mg/m2/d for 21 days).
  • Assessment of response rates in patients with germ cell tumors, SCLC, and other selected cancers.
  • Evaluation of etoposide absorption rates on the prolonged schedule.

Related Experiment Videos

Main Results:

  • Chronic oral etoposide demonstrated occasional responses in resistant tumors.
  • Higher-than-expected response rates were observed in patients with germ cell tumors and SCLC.
  • Nearly 90% etoposide absorption was noted with the 21-day low-dose schedule.

Conclusions:

  • A prolonged 21-day schedule may represent a novel approach to etoposide administration, potentially enhancing its therapeutic value.
  • Further research into etoposide's schedule dependency is warranted.
  • Etoposide shows utility in gastric, ovarian, and poorly differentiated carcinomas of unknown primary site, with potential for combination therapies.